Their research data showed that this degradation agent can inhibit the proliferation of A549 cells by downregulating the level of MIF in non-small cell lung cancer A549 cells and inhibiting MIF-related signal transduction, proving the potential of PROTAC technology in the treatment of NSCLC [71]. Here, MIF is linked to non-small cell lung carcinoma.